# Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

> **NCT01050062** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1452 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan 80mg
- **DRUG:** Telmisartan 40mg
- **DRUG:** Hydrochlorothiazide 12.5mg

## Key facts

- **NCT ID:** NCT01050062
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 1452 (ACTUAL)
- **Last updated:** 2014-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01050062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01050062, "Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01050062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*